Previous work indicating that NGF protein loops 2 and 4 interact with TrkA receptors raise the possibility that small molecule mimetics corresponding to TrkAinteracting domains that have NGF agonist activity can be developed. We applied our previously developed strategy of dimeric peptidomimetics to address the hypothesis that loop 4 small molecule dimeric mimetics would activate TrkA-related signal transduction and mimic NGF neurotrophic effects in a structure-specific manner. A loop 4 cyclized peptide dimer demonstrated NGF-like neurotrophic activity while peptides with scrambled sequence, added or substituted residues, or cyclized in monomeric form were inactive. Activity was blocked by the TrkA inhibitors K252a and AG879 but not by NGF p75 receptor blocking antibody. Dimeric, but not monomeric, peptides partially blocked NGF activity. This profile was consistent with that of a NGF partial agonist. ERK and AKT phosphorylation was stimulated only by biologically active peptides and was blocked by K252a. The ERK inhibitor U0126 blocked the neurite-but not the survivalpromoting activity of both NGF and active peptide. These studies support the proof-ofconcept that small molecule NGF loop 4 mimetics can activate NGF signaling pathways and can mimic death-preventing and neurite-promoting effects of NGF. This finding will guide the rational design of NGF single-domain mimetics and contribute to elucidating NGF signal transduction mechanisms.
Introduction
Nerve growth factor (NGF) acts via TrkA and p75 receptors to regulate neuronal survival, promote neurite outgrowth and upregulate certain neuronal functions such as mediation of pain and inflammation (1, 2, 3, 4, 5) . These actions suggest that NGF agonists or antagonists might be useful in regulating these processes (6, 7, 8) . Factors limiting therapeutic applications of the NGF protein include restricted penetration of the CNS and the poor medicinal properties characteristic of most proteins (9, 10) . The development of small molecule mimetics with favorable chemical properties that function as agonists or antagonists that mimic or inhibit NGF functions in the appropriate biological context will be critical in advancing potential in vivo applications of NGF. Moreover, in settings in which NGF might contribute to neuronal death, pain or inflammatory mechanisms, NGF antagonists may be particularly relevant. Creation of single domain NGF mimetics will also constitute a powerful approach for linking specific NGF domains with specific patterns of intracellular signal transduction.
A NGF mimetic (agonist or antagonist) would be expected to contain structural determinants of one or more NGF active sites that interact with NGF receptors. Multiple techniques have been used to deduce which domains of the NGF protein interact with NGF receptors (11) . A peptide mapping approach in which synthetic peptides with sequences corresponding to specific NGF regions were tested for their ability to inhibit NGF activity pointed to residues 29-35 as a key active site (12) . Subsequent NGF crystallography and molecular modeling studies revealed that NGF contains three surface hydrophilic β-hairpin loops (loops 1, 2 and 4) that are likely candidates for receptor interaction sites (13, 14, 15) . Loop 1 consists of the previously mapped residues [29] [30] [31] [32] [33] [34] [35] and subsequent studies confirmed that region 29-35 synthetic peptides inhibited NGF activity and NGF p75 receptor binding (16) . Recombinant substitution studies indicated by guest on http://www.jbc.org/ Downloaded from that residues Lys 32 and Lys 34 (17) and other residues (18) are likely to interact with p75
receptors. The NGF sites interacting with TrkA have also been derived via chemical modification (11, 19, 20) , recombinant protein (18, 20, 21, 22, 23) and NGF-TrkA cocrystalization approaches (24) . Taken together, these studies indicate that TrkA binding sites consist of residues in NGF loop 2 (residues 40-49), loop 4 (residues 91-97), the Nterminus (residues 1-8) and the C-terminus (residues 111-115).
We have established that synthesis of peptide derivatives mimicking single NGF domains provides an approach for deriving the proof-of-concept that mimetics of a given single-site domain can function as NGF antagonists or agonists (12, 25) . This approach has demonstrated that a cyclized dimer, but not linear or cyclized monomer peptides, corresponding to NGF loop 1 can function as a NGF agonist to prevent neuronal death via a p75-dependent, Trk kinase-independent signaling mechanism (25) . 
Experimental Procedures
Peptide synthesis, purification and characterization. Methods for peptide synthesis, purification and characterization were conducted as previously described (25) . Peptides were synthesized in the C-terminal amide form by Peninsula Laboratories (Belmont, CA)
following our specifications. The amide form was chosen in order to reduce susceptibility to proteolytic cleavage. Peptide conformation was stabilized by cyclization (32, 33) .
Cysteine or penicillamine (β,β-dimethylcysteine) residues were added to each end of the linear sequence to provide sulfhydryl groups for oxidative peptide cyclization.
Penicillamine has been found to facilitate cyclization and to provide greater conformational constraint relative to cysteine-cysteine cyclization (33, 34) . Peptides were cyclized into monomeric or dimeric forms via oxidative formation of disulfide bonds by the addition of K3[Fe(CN)6] to peptides solubilized in water at either low (monomeric cyclization) or high (dimeric cyclization) concentrations (34) . Following cyclization, peptides were lyophilized and then purified by reversed-phase HPLC (12, 25) . Analytical HPLC was used to confirm purity of >98%.
One aliquot from each purified HPLC fraction was used for quantitative amino acid analysis to confirm peptide composition and to determine concentration. The composition and cyclized state of each peptide was further confirmed using matrixassisted laser desorption/ionization (MALDI) mass spectrometry to determine molecular mass (AnaSpec Inc., San Jose, CA). Prior to each bioassay, peptide aliquots were lyophilized and resuspended to known concentrations in culture media.
Bioassays for neurotrophic activity. Dorsal root ganglia were dissected from embryonic day 8 chick embryos and placed in calcium and magnesium-free Dulbecco's balanced salt solution on ice. Ganglia were then resuspended and incubated for 20 min in 2. For six well plate studies (Costar 9.5 cm 2 /well) wells were pre-coated with 1.0 ml/well of polyornithine and 1.0 ml/well of laminin at the concentrations listed above.
Highly purified neuronal preparations were obtained by incubating DRG cell mixtures in 100 mm diameter plastic tissue culture dishes coated with type I rat tail collagen (Collaborative Biomedical Products) (35) . Cells were incubated for 2.5 hrs at 37 o C in 5% 
Results
A dimeric peptide containing NGF residues 92-96 functions as a partial agonist. In previous studies we determined that dimerization via cysteine and penicillamine residues was required for activity of NGF loop 1 peptidomimetics (24) . Therefore, an analogous approach was applied to NGF loop 4 peptides (Figure 1a) . In a first series of assays the effects of peptide P92 and various control peptides on neuronal survival were determined using a standard twenty-four hour assay of NGF survival promoting activity (25 Dimeric peptide P92 promoted neuronal survival at a level three-fold higher than baseline survival levels and 10-15% of the maximum survival promoted by NGF (Figure 1b) .
This effect was dose-dependent over a range of 8-125 µM. In separate studies, doses up to 250 µM showed no further increase in survival promoting effect, suggesting that P92 was functioning as a NGF partial agonist rather than full agonist. The term partial agonist is used in the present study to describe a ligand producing a maximum response lower than the maximum response produced by the full or native (i.e. NGF) agonist (37) .
Structure-function studies based on P92 variants were conducted (Figure 1 b-d) .
The monomeric form of P92 had no activity, indicating that the survival promoting effect of P92 was dimer-dependent. The activity of P92 was lost entirely if residues were scrambled (P92S) or if the amide terminus cysteine was substituted with a penicillamine residue (P92P). For peptide P90, amino acid residues were added at either end in order to flank the cysteine and penicillamine moieties and further restrain peptide conformation.
This approach for additional structural constraint led to increased potency for cyclic RGD-containing fibronectin peptides (34) . In the case of the P92 peptide, activity was lost entirely when flanking residues were added. These structure-function studies demonstrated that the activity of P92 was highly sequence-and structure-dependent. indicated that the P92 dimer activity profile was structure-dependent.
P92 displays
P92 demonstrates neurotrophic activity in long-term cultures. In long-term DRG cultures (greater than twenty-four hours), NGF promotes both neuronal survival and neurite outgrowth (39) . In order to determine whether P92 activity also resembled that of NGF beyond the twenty-four hour period, assays underwent two key modifications.
Highly purified preparations of neurons were obtained so that the presence of proliferating non-neurons would be minimized. In addition, six well plates were used allowing neurons to be plated at very low densities allowing greater area for neurite outgrowth. Under these conditions, assessment of the number of surviving neurons per area showed that P92 supported survival at levels two-fold greater than background and at 38% of the NGF maximum survival activity in both one-day and three-day cultures (Figure 2 ). This level of activity, measured as a percentage of the NGF effect, was more than two-fold higher than the 10-15% range observed using the standard ninety-six well assays. Monomeric and scrambled forms of P92 had no activity, again demonstrating that P92 NGF mimetic activity was structure-and sequence-dependent. The morphological features of DRG cultures supported by NGF and peptides are shown in Figure 3 . Gross cellular morphology and overall neurite outgrowth patterns appeared similar in NGF and P92 treated cultures. In six well plate cultures, essentially all NGF-and P92-supported surviving neurons were associated with neurites. This pattern was in marked contrast to NGF loop 1 peptidomimetics which primarily promoted neuronal survival with relatively less effect on neurite outgrowth (25) .
The survival-promoting activity of P92 is blocked by TrkA inhibitors but not by p75
antibody. Inhibitors of the TrkA and p75 receptors known to block NGF activity were used to further test the hypothesis that P92 acts via NGF signaling mechanisms. Although no inhibitor entirely specific for TrkA is available, K252a is relatively specific for TrkA (40, 41, 42) and would be expected to block activity of P92 if its action were TrkAdependent. Similarly, the TrkA inhibitor AG879 (43) would also be expected to block P92. Since the tyrosine kinase targets of K252a and AG879 are partially non-overlapping (41, 43) , inhibition of P92 by both compounds would further support the hypothesis that P92 acts via TrkA. As shown in Figure 4 , the TrkA inhibitor K252a blocked NGF activity by 66% and P92 activity by 49%. AG879 blocked NGF by 85% and P92 activity by 66%. In contrast, p75 receptor antibody partially blocked NGF as previously established (25, 36) but had no effect on P92 activity. These findings supported the hypothesis that P92 prevented neuronal death primarily via TrkA receptors. 48) . As established by these previous studies, ERK and AKT activation were assessed using the ERK and AKT phosphorylation assays. As shown in Figure 5A and 5B P92 induced ERK activation. At the 10 and 30 minute time points, P92 induced ERK activation to 17% and 16% of the levels induced by NGF, respectively. At the 3 hour time point, P92-induced ERK activation remained above baseline at 9% of NGF levels.
P92 induces ERK and AKT activation.
The relative level of P92-induced ERK signaling was proportional to its relative neurotrophic efficacy as compared to NGF. The hypothesis that P92 acts via TrkA receptors also predicted that the TrkA inhibitor K252a would block P92 induced ERK activation. As shown in Figure 5C , K252a blocked ERK activation induced by both NGF and P92.
P92 also induced AKT activation ( Figure 6A and 6B) . At the 10 and 30 minute time points, P92 induced AKT activation to 26% and 66% of the levels induced by NGF, respectively. At the 3 hour time point, P92-induced ERK activation remained above baseline at 14% of NGF levels. Consistent with the partial agonist effect of P92, the degree of AKT activation was less than that induced by NGF. The hypothesis that P92 acts via TrkA receptors also predicted that the TrkA inhibitor K252a would block P92 induced AKT activation. As shown in Figure 6C , K252a blocked AKT activation induced by both NGF and P92.
ERK Inhibitor U0126 blocks NGF-and P92-induced neurite outgrowth but not neuronal survival. The hypothesis that the P92 mimics NGF via ERK signaling was
further assessed using the ERK inhibitor U0126 and its inactive chemical control U0124 (49) . As shown in Figure 7 , U0126, but not U0124 inhibited neurite outgrowth induced by both NGF and P92. Quantitative analysis of neuronal survival showed that U0126 had no effect on cell survival supported by NGF. The survival level in the presence of U0126 was 99.5% of that measured without U0126. Similarly, U0126 had no effect on cell Fourth, the biological profile elicited by P92 of both preventing neuronal death and stimulating neurite outgrowth parallels that triggered by NGF interaction with TrkA.
Fifth, the absolute requirement of dimerization for P92 activity is consistent with models in which the NGF protein dimer induces receptor dimerization. Sixth, P92 activity was blocked by the TrkA inhibitors K252a and AG879. While inhibitors entirely specific for
TrkA are not available, the largely non-overlapping tyrosine kinase target profiles of these Trk inhibitors suggests that P92 activity is TrkA-dependent. Seventh, P92
stimulates ERK and AKT activation. In addition, the lower amplitudes of ERK and AKT activation compared to that of NGF are consistent with the partial efficacy of P92. As found with NGF, P92-induced ERK and AKT activation was blocked by K252a. Eighth, the neurite outgrowth activity but not the survival promoting activity of both NGF and P92 was blocked by the ERK inhibitor U0126.
Given 
